Search academic texts

Information × Registration Number 0221U100971, 0118U003022 , R & D reports Title Optimization of maintenance therapy with intravenous immunoglobulins of patients with B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma/ popup.stage_title Head Tymchenko Anatoliy S, Доктор медичних наук Registration Date 11-01-2021 Organization State Institution "Institute of Hematology and Transfusiology NAMS Ukraine" popup.description2 Object of research - the patients with B-cell chronic lymphocytic leukemia/ small lymphocyte lymphoma (B-CLL/SLL), blood and blood serum of patients with B-CLL /SLL. Aim of of research - to determine the optimal therapy regimens for the accompaniment of intravenous immunoglobulins (IVIG) in patients with B-CLL /SLL in the course of chemotherapy (CT). Research methods - general clinical, morphological, immunological, biochemical, instrumental, statistical. 62 patients with B-CLL/SLL were examined: 32 patients with B-CLL, 30 - with B-cell SLL. The experimental group of patients consisted of patients who were diagnosed with B-CLL /SLL for the first time (primary patients, n = 20) and patients with B-CLL/SLL who received preliminary CT (n = 42). A study of general clinical parameters, the content of the main classes of immunoglobulins (IgG, IgA, IgM), indicators of cellular immunity, the fractional composition of blood serum proteins and electrocardiogram, systemic hemodynamics and cardiohemodynamics by the beginning of CT (initial data). In patients with B-CLL/SLL, a wide range of differences in the initial indicators of the content of the main Ig classes in the blood serum (from hypo- to hyperglobulinemia) was revealed. Analysis of the research results substantiates the need to use IVIg replacement therapy in the complex accompanying therapy of patients with B-CLL/SLL, as well as to maintain cardiac activity - drugs of metabolic action. The criteria for prescribing IVIG replacement therapy in patients with B-CLL/SLL may be: 1) a decrease in the serum IgG content below 6.0 g/l; 2) the occurrence of a severe (according to WHO criteria) or recurrent infectious-inflammatory complications (IIC) in a patient 3) ineffective antibiotic therapy of IIC. The developed algorithm for prescribing IVIg replacement therapy in patients with B-CLL/SLL made it possible to optimize the IVIG regimen for this pathology. Branch of application-medicine.Medical and social effect.The mediсine Product Description popup.authors Vergun Liubov Yu Lanovenko Ivan I Rybalska Alla P. Sivkovych Svitlana O Sergutina Svitlana Yu Starovoit Viktoria V Tymchenko Anatolii S popup.nrat_date 2021-01-11 Close